At the completion of the clinical evaluation, based on the information received, there were evidence to support the reported endoleak.It was confirmed that patient had an el3a (mfg report mdr: 2031527-2017-00542); a complete component separation; and a secondary endovascular intervention.In addition, a stent cage dilation of the cuff and main body stent (mfg report mdr: 2031527-2017-00542),( 24% and 36% respectively).The most likely cause of the loss of seal and implant separation was the use of strata material in combination[ due to the presence of stent cage dilation] with severe aortic remodeling (anatomy).The patient's disposition post repair could not be ascertained; there were no further reports of negative patient sequelae.The review of manufacturing lot confirmed all devices met specifications prior to release.The lot usage history shows that no other units from the affected lots have been involved in any similar complaints at this time.No device will be returned as the device remains implanted in the patient.Endologix continues to investigate this event and similar events to ensure the highest quality and patient safety.
|